One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine (Plaquenil), a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Lc3 mitotracker chloroquine Hydroxychloroquine ears The American Academy of Ophthalmology has published several dosing and screening recommendations for hydroxychloroquine to avoid potential retinal toxicity, yet some patients still experience. In 2002, the American Academy of Ophthalmology AAO established ocular examination guidelines for screening patients on Plaquenil therapy. Testing included a comprehensive eye exam that consisted of an assessment of the posterior segment with careful evaluation of associated macular changes or signs of retinal disease. 4 Baseline fundus. Plaquenil. The new guidelines- 2011 American Academy of Ophthalmology Offer new dosing and screening protocols How often for objective test screening? Baseline 5 years* Yearly after 5 years of initiating therapy *May consider screening sooner than 5 years if risk factors are present 2016. Who to screen for toxicity? High Risk It is imperative that patients and physicians are aware of and watch for this drug’s ocular side effects. Retinal toxicity from hydroxychloroquine is rare, but even if the medication is discontinued, vision loss may be irreversible and may continue to progress. Plaquenil screening guidelines aao Update on Screening Recommendations for Hydroxychloroquine., New Plaquenil Guidelines Plaquenil hot flashesHydroxychloroquine and sun exposure My Take on New Ocular Screening Guidelines for Plaquenil By Sergio Schwartzman, MD 12 October 2016. A recent article published by the American Academy of Ophthalmology AAO presented new recommendations for screening of patients being managed with hydroxychloroquine HCQ. In this article, new recommendations were made that changed the. My Take on New Ocular Screening Guidelines for Plaquenil.. PowerPoint. Update on Plaquenil Testing. RCOphth guideline Hydroxychloroquine and Chloroquine.. Reused, with permission, from American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy, Revised 2016. The Ophthalmic News and Education Network, American Academy of Ophthalmology. The latest screening guidelines were published in 2016 by the American Academy of Ophthalmology Table 1. The most important risk factors are dosage and duration of use. Dosage greater than 5.0mg/kg over five years dramatically increases the risk of retinal toxicity, and high doses can be exceedingly dangerous. Aug 30, 2011 Newer guidelines state that daily dose 5mg/kg of real weight/day can lead to toxicity. Retinal toxicity is irreversible and can progress after cessation of hydroxychloroquine, thus early screening is important to limit potential vision loss. Baseline screening and annual screening after five years is recommended.